[go: up one dir, main page]

AR123228A1 - SOLID STATE FORMS OF AN ORGANIC COMPOUND - Google Patents

SOLID STATE FORMS OF AN ORGANIC COMPOUND

Info

Publication number
AR123228A1
AR123228A1 ARP210102263A ARP210102263A AR123228A1 AR 123228 A1 AR123228 A1 AR 123228A1 AR P210102263 A ARP210102263 A AR P210102263A AR P210102263 A ARP210102263 A AR P210102263A AR 123228 A1 AR123228 A1 AR 123228A1
Authority
AR
Argentina
Prior art keywords
solid state
state forms
organic compound
conditions
forms
Prior art date
Application number
ARP210102263A
Other languages
Spanish (es)
Inventor
Kristopher Depew
Louis Grenier
Benjamin S Lane
Eric Simone
Jacob Paul Sizemore
Lizarraga Jose Luis Rios
Original Assignee
Servier Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Pharmaceuticals Llc filed Critical Servier Pharmaceuticals Llc
Publication of AR123228A1 publication Critical patent/AR123228A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

En el presente documento se proporcionan varias formas en estado sólido, que incluyen sales, así como varias formas cristalinas y amorfas, del Compuesto I, que está representado por la fórmula estructural: de fórmula (1). También se proporcionan composiciones farmacéuticas que comprenden estos materiales, métodos para su fabricación, usos de los mismos para tratar afecciones, incluidas, entre otras, afecciones que se beneficiarían de la inhibición de la metionina adenosiltransferasa 2a (MAT2A).Provided herein are various solid state forms, including salts, as well as various crystalline and amorphous forms, of Compound I, which is represented by the structural formula: of formula (1). Also provided are pharmaceutical compositions comprising these materials, methods for their manufacture, uses thereof to treat conditions, including, but not limited to, conditions that would benefit from inhibition of methionine adenosyltransferase 2a (MAT2A).

ARP210102263A 2020-08-12 2021-08-12 SOLID STATE FORMS OF AN ORGANIC COMPOUND AR123228A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063064866P 2020-08-12 2020-08-12

Publications (1)

Publication Number Publication Date
AR123228A1 true AR123228A1 (en) 2022-11-09

Family

ID=77693586

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210102263A AR123228A1 (en) 2020-08-12 2021-08-12 SOLID STATE FORMS OF AN ORGANIC COMPOUND

Country Status (3)

Country Link
AR (1) AR123228A1 (en)
TW (1) TW202227446A (en)
WO (1) WO2022036033A2 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE386506T1 (en) * 1995-10-17 2008-03-15 Jagotec Ag ADMINISTRATION OF INSOLUBLE DRUGS
AU2015229212B2 (en) 2014-03-14 2019-06-20 Les Laboratoires Servier Pharmaceutical compositions of therapeutically active compounds
WO2018039972A1 (en) * 2016-08-31 2018-03-08 Agios Pharmaceuticals, Inc. Inhibitors of cellular metabolic processes
KR102411150B1 (en) 2016-08-31 2022-06-21 아지오스 파마슈티컬스 아이엔씨. inhibitors of cellular metabolic processes
MX2020004513A (en) 2017-11-02 2020-09-17 Agios Pharmaceuticals Inc COCRYSTALS, PHARMACEUTICAL COMPOSITIONS THEREOF AND METHODS OF TREATMENT INVOLVING THEM.

Also Published As

Publication number Publication date
TW202227446A (en) 2022-07-16
WO2022036033A4 (en) 2022-06-23
WO2022036033A3 (en) 2022-04-21
WO2022036033A2 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
CL2019000986A1 (en) 1.3 di cyclobutane substitute or azetidine derivatives as prostaglandin d synthase hematopoietic inhibitors (h-pgds).
CO6341623A2 (en) ORGANIC COMPOUNDS
CL2021000844A1 (en) Indolinone compounds for use as inhibitors of map4k1
CU20190101A7 (en) SUBSTITUTED DIAZABICYCLIC IMIDAZOPYRIMIDINES
DOP2016000308A (en) COMPOUNDS OF 1, 3, 4-TIADIAZOL AND USE OF THE SAME FOR THE TREATMENT OF CANCER
UY37774A (en) SUBSTITUTED 5-CYANOINDOL COMPOUNDS AND USES OF THE SAME
CL2024003450A1 (en) Compounds and uses of these
CL2020003248A1 (en) N-substituted tetrahydrothienopyridine derivatives and their uses
MX374295B (en) TLR7 AGONIST MALEATE SALT, ITS CRYSTALLINE FORMS C, D AND E, ITS PREPARATION METHODS AND USES OF MALEATE SALT AND CRYSTALLINE FORMS.
PE20171348A1 (en) 4-SUBSTITUTED BENZOXABOROL COMPOUNDS AND USE OF THEM
AR117844A1 (en) THIAZOLOPYRIDINE DERIVATIVES AS ANTAGONISTS OF THE ADENOSINE RECEPTOR
CL2017000827A1 (en) Aldosterone synthase inhibitors
CL2021001640A1 (en) Salt and crystalline forms of an organic compound and pharmaceutical compositions thereof
CO2025003099A2 (en) Compounds for cancer treatment
CL2023002633A1 (en) Uracil derivatives as trpa1 inhibitors
CO2025003090A2 (en) Substituted pyridinone compounds as cbl-b inhibitors
CL2025000161A1 (en) Cyclic compounds and methods of using same.
CL2023003921A1 (en) Transglutaminase inhibitors
CO2023013700A2 (en) Compounds to regulate trained immunity and methods of using them
AR123228A1 (en) SOLID STATE FORMS OF AN ORGANIC COMPOUND
ECSP24007193A (en) PYRIMIDINE COMPOUNDS FOR USE AS MAP4K1 INHIBITORS
CL2023003979A1 (en) Transglutaminase inhibitors
ECSP24007534A (en) TRANSGLUTAMINASE INHIBITORS
AR090959A1 (en) ANALOGS OF HEXADEPSIPEPTIDES AS ANTI-BANGEOUS COMPOUNDS
MX2024013840A (en) Pyrazine derivatives and uses thereof

Legal Events

Date Code Title Description
FB Suspension of granting procedure